Dose administration for the first subjects in its recently approved clinical study with drug candidate, CS1
Read more here.
Year-end report 2017 The Board and Chief Executive Officer of Cereno Scientific AB...
Interim report: 1 January – 30 September 2017 The board of directors and the CEO of Cereno Scientific...
Cereno Scientific announces first subjects dosed in clinical study with drug candidate CS1 Cereno Scientific (Aktietorget: “CRNO B”), a pharmaceutical company developing a...
Year-end report 2017 22 February 2018
We are proud supporters of World Thrombosis Day. Read more here.